Global /Japan /Healthcare /Biotechnology /4888

Stella Pharma Corp.

4888

• TSE: 4888 • Delayed

514JPY -1%

3.21 USD

As of 5 June 2026, Stella Pharma Corp. has a market cap of $113.62M USD, ranking #24672 globally and #2141 in Japan. It ranks #2208 in the Healthcare sector, and #426 in the Biotechnology industry.

Global Rank

24672

Country Rank

2141

Sector Rank

2208

Industry Rank

426

Key Stats

Market Cap

$113.62MUSD

18.18B JPY

Enterprise Value

$101.72MUSD

16.28B JPY

Revenue (TTM)

$6.05MUSD

968.0M JPY

EBITDA (TTM)

-$1.22MUSD

-194.75M JPY

Net Income (TTM)

-$1.74MUSD

-279.0M JPY

EBITDA Margin

-20%

Profit Margin

-29%

PS Ratio

18.8

PB Ratio

6.7

Company Profile

Country (HQ)

Japan

Sector

Healthcare

Industry

Biotechnology

CEO

Koki Uehara open_in_new

Employees

Founded

2007

Website

stella-pharma.co.jp open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-1%	-18%	-41%	61%	58%	154%	63%	41%	-22%

News

Markets

Exchange	Ticker	Price	Quotes
Tokyo Stock Exchange (TSE / TYO) MIC: XTKS PRIMARY	4888 ステラファーマ株式会社 Ordinary Shares ISIN: JP3399680002 Shares Out.: Shares Outstanding: 35.02M¹ Shares Float: 21.138M² TV: TradingView: TSE: 4888 SA: Stock Analysis: TYO: 4888 YF: Yahoo Finance: 4888.T GF: Google Finance: TYO: 4888 BA: Barron's: 4888 MS: Morningstar: XTKS: 4888	514 JPY	TV: TradingView: TSE: 4888 SA: Stock Analysis: TYO: 4888 YF: Yahoo Finance: 4888.T GF: Google Finance: TYO: 4888 BA: Barron's: 4888 MS: Morningstar: XTKS: 4888

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Stella Pharma Corp.

Stella Pharma Corporation engages in the research, development, manufacturing, and distribution of pharmaceuticals. The company develops drugs for boron neutron capture therapy (BNCT). Its products include SPM-011, a boron-containing drug for BNCT used for treating head and neck cancer, recurrent malignant glioma, meningioma, and malignant melanoma and angiosarcoma. The company was incorporated in 2007 and is headquartered in Osaka, Japan.

Similar Companies

Industry: Biotechnology (Japan)

Name	Market Cap (USD) diff.	PE	Country
GNI Group Ltd. TSE: 2160	$1.02B 162.8B JPY 795%	-	Japan
PeptiDream Inc. TSE: 4587	$929.38M 148.73B JPY 718%	-	Japan
Oncolys BioPharma Inc. TSE: 4588	$526.3M 84.22B JPY 363%	-	Japan
Cuorips Inc. TSE: 4894	$349.85M 55.99B JPY 208%	-	Japan
Innovacell Inc. TSE: 504A	$169.94M 27.19B JPY 50%	-	Japan
SUSMED,Inc. TSE: 4263	$96.24M 15.4B JPY -15%	-	Japan

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 160K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 141K%	19.0	United States
argenx SE EBR: ARGX	$48.01B 41.39B EUR 42K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.48B 68.19T KRW 39K%	35.5	South Korea
CSL Ltd. ASX: CSL	$43.01B 60.27B AUD 38K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.72B 33.71B CHF 37K%	37.2	Switzerland

chevron_leftBack